- Home
- VERU
VERU
Veru Inc.
as 02-21-2025 4:00pm EST
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 108.8M | IPO Year: | 1990 |
| Target Price: | $4.00 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $1.92 | Next Earning Date: | 02-13-2025 |
| Revenue: | $16,886,419 | Revenue Growth: | 22.46% |
| Revenue Growth (this year): | -59.04% | Revenue Growth (next year): | -11.51% |
Stock Insider Trading Activity of Veru Inc. (VERU)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rankowitz Michael L | VERU | Director | Feb 18 '25 | Buy | $0.57 | 150,000 | $84,350.79 | 195,279 |
Latest Veru Inc. News
VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
3 US Penny Stocks With Market Caps Under $300M To Consider
GuruFocus.com
8 days ago
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...
GlobeNewswire
9 days ago
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
GuruFocus.com
10 days ago
Veru Inc (VERU) Q1 2025 Earnings Report Preview: What To Expect
GlobeNewswire
16 days ago
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
GlobeNewswire
18 days ago
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BioPharma Dive
a month ago
Muscle-building drug improves body composition in obesity trial, Veru says
GlobeNewswire
a month ago
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
Compare VERU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERU Veru Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.